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Abstract
Background: Positron emission tomography imaging of lung cancers with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose is 
a non-invasive diagnostic, and prognostic tool that measures tumor metabolism. We have analyzed the effect of solute 
carrier family 2 (facilitated glucose transporter), member 1 polymorphisms on 2-[fluorine-18]-fluoro-2-deoxy-D-
glucose-uptake with a combination of polymorphisms of hypoxia-inducible factor 1 alpha, apurinic/apyimidinic 
endonuclease, and vascular endothelial growth factor A in a hypoxia-related pathway.
Methods: We investigated the association between solute carrier family 2 (facilitated glucose transporter), member 1 -
2841A>T, hypoxia-inducible factor 1 alpha Pro582Ser, Ala588Thr, apurinic/apyimidinic endonuclease Asp148Glu, or 
vascular endothelial growth factor A +936C>T and 2-[fluorine-18]-fluoro-2-deoxy-D-glucose-uptake among 154 
patients with non-small-cell lung cancer.
Results: The solute carrier family 2 (facilitated glucose transporter), member 1 -2841A>T polymorphism was 
significantly associated with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose-uptake in combination with the apurinic/
apyimidinic endonuclease Asp148Glu (T>G) polymorphism in the squamous cell type of non-small-cell lung cancer. 
The solute carrier family 2 (facilitated glucose transporter), member 1 TT genotype had a higher maximum 
standardized uptake values than the AA + AT genotype when the apurinic/apyimidinic endonuclease genotype was 
TT (mean maximum standardized uptake values, 12.47 ± 1.33 versus 8.46 ± 2.90, respectively; P = 0.028). The mean 
maximum standardized uptake values were not statistically different with respect to vascular endothelial growth factor 
A and hypoxia-inducible factor 1 alpha polymorphisms.
Conclusion: A glucose transporter gene polymorphism was shown to be statistically associated with glucose-uptake 
when the apurinic/apyimidinic endonuclease genotype is TT in patients with the squamous cell type of non-small-cell 
lung cancer. Our findings suggest that a newly developed tracer for positron emission tomography could be affected 
by genetic polymorphisms.
Introduction
Positron emission tomography (PET) imaging of malig-
nant tumors with 2-[fluorine-18]-fluoro-2-deoxy-D-glu-
cose (FDG) as a tracer (FDG uptake depends on glucose
uptake) is a non-invasive diagnostic, and prognostic tool
that measures tumor metabolism. FDG-PET has been
shown to have the ability to diagnose disease. Moreover,
FDG-PET is used for treatment planning and is used to
evaluate the response to therapy [1]. The SLC2A1 (also
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called glucose transporter type 1, GLUT1) gene is the pri-
mary glucose transporter gene in human lung cancer [2].
Hypoxia-inducible factor 1a (HIF-1a) controls oxygen
delivery via angiogenesis and metabolic adaptation to
hypoxia via glycolysis [3]. HIF-1a regulates SLC2A1 gene
expression in cells that are subjected to hypoxic condi-
t i o n s  [ 4 ] .  M a n y  c e l l u l a r  p r o t e i n s  i n t e r a c t  w i t h  o r  a r e
under the control of HIF1-a. HIF-1a overexpression and
enhanced transcriptional activity are linked to tumor ini-
tiation and progression. Indeed, a large number of clini-
copathologic studies have confirmed that unlike mature
normal tissues, HIF-1a is overexpressed in the cytoplasm
and nuclei of 40%-80% of human carcinomas, including
lung, breast, head and neck, endometrial cancers, mela-
nomas, and sarcomas [5,6]. Recently, Fu et al. [7] and
Koukourakis et al. [8] showed that a HIF1A gene poly-
morphism affected HIF-1a protein expression.
The expression of the downstream SLC2A1 and vascu-
lar endothelial growth factor (VEGF) genes are regulated
by a HIF1A-activated transcription pathway. VEGFA is
the major mediator of angiogenesis and vascular permea-
bility and transcription of this gene under hypoxic condi-
tions depends on HIF-1a induction. A C>T
polymorphism at position 936 in the 3' untranslated
region of the VEGFA gene has been associated with the
plasma levels of VEGFA  [9]. The T variant, which is
linked to lower VEGFA levels, has been associated with
colon cancer [10] and low FDG uptake [11]. These find-
ings suggest a potential role of the VEGFA 936C>T poly-
morphism for the variability of FDG uptake in tumor
tissues.
One important mammalian redox modulator is the
bifunctional enzyme Redox factor-1 (Ref-1, also termed
APEX1), that promotes transcriptional activation of HIF-
1 or hypoxia inducible factor-like factor (HLF) by reduc-
ing C-terminal domain of HIF-1 or HLF [12], although
the major role of this enzyme is DNA base excision repair
[13]. Recently, APEX polymorphisms have been the focus
of studies involving several different types of cancer,
including colorectal [14], breast [15], and non-small cell
lung cancer (NSCLC) [16]. These results suggested the
involvement of APEX1 in the development of lung cancer.
The proteins encoded by SLC2A1  and  VEGFA  are
under the control of HIFA gene expression. An effect of
these gene polymorphisms on glucose uptake to modify
FDG-uptake could be influenced by the interaction of
proteins in a common pathway. In this study, we have
determined the impact of SLC2A1  polymorphisms on
FDG-uptake (maximum standardized uptake value
[SUVmax]) using a pathway-based approach with a com-
bination of HIFA,  APEX1, and VEGFA  gene polymor-
phisms that might influence glucose uptake.
Materials and methods
1. Patient characteristics
Patients suspected of having lung cancer were prospec-
tively recruited between October 2005 and October 2008.
The inclusion criteria were as follows: (1) patients had a
pathologically-confirmed diagnosis of NSCLC (2) and
peripheral blood lymphocytes and FDG-PET images
were available for analysis. Patients had a standard stag-
ing work-up that included fibroscopy, a chest and abdom-
inal CT scan, brain MRI or CT imaging, and FDG-PET.
One hundred fifty-four patients with NSCLC met the
inclusion criteria with a median follow-up time of 7.5
months (range, 0.13 - 29.5 months). There were 62 deaths
(40.3%) during the study period.
Single nucleotide polymorphism Selection
Single nucleotide polymorphisms (SNPs) were chosen for
non-synonymous coding polymorphisms or for clini-
cally-associated polymorphisms described in previous
studies. The following SNPs were selected in this study:
SLC2A1  -2841A>T (rs710218), VEGFA+936C>T
(rs3025039) [NM_001025366.1:c.*237C>T], APEX1
Asp148Glu (T>G, rs1130409) [NM_001641.2:c.444T>G],
HIF1A  Pro582Ser (C>T, rs11549465)
[NM_001530.2:c.1744C>T], and HIF1A  Ala588Thr
(G>A, rs11549467) [NM_001530.2:c.1762G>A].
Genotyping
The SNaPshot assay was performed according to the
manufacturer's instructions (ABI PRISM SNaPShot Mul-
tiplex kit; Applied Biosystems, Foster City, CA, USA).
Briefly, the genomic DNA flanking the SNP of interest
was amplified with the use of a PCR reaction with for-
ward and reverse primer pairs and standard PCR
reagents. The 10 μL reaction volume contained 10 ng of
genomic DNA, 0.5 pM of each oligonucleotide primer, 1
mL of 10× PCR buffer, 250 μM dNTP (2.5 mM each), and
0.25 units i-StarTaq DNA Polymerase (5 units/μL;
iNtRON Biotechnology, Sungnam, Kyungki-Do, Korea).
PCR reactions were carried out as follows: 10 min at 95°C
for 1 cycle, and 35 cycles at 95°C for 30 s, followed by 1
extension cycle at 72°C for 10 min. After amplification,
the PCR products were treated with 1 U each of shrimp
alkaline phosphatase (SAP) and exonuclease I (Roche
Diagnostics, Mannheim, Germany) at 37°C for 75 min
and 72°C for 15 min to purify the amplified products.
One μL of the purified amplification products was added
to a SNaPshot Multiplex Ready reaction mixture contain-
ing 0.15 pmol of genotyping primer for a primer exten-
sion reaction. The primer extension reaction was carried
out for 25 cycles of 96°C for 10 sec, 50°C for 5 sec, and
60°C for 30 sec. The reaction products were treated with
1 U of SAP at 37°C for 1 hr and 72°C for 15 min to remove
excess fluorescent dye terminators. One μL of the final
reaction samples containing the extension products wasKim et al. Journal of Experimental & Clinical Cancer Research 2010, 29:69
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added to 9 μL of Hi-Di formamide (Applied Biosystems).
The mixture was incubated at 95°C for 5 min, followed by
5 min on ice, then the mixture was analyzed by electro-
phoresis on an ABI Prism 3730xl DNA analyzer. Analysis
was carried out using Genemapper software (version 3.0;
Applied Biosystems). Table 1 shows the primer sets and
Tm used for the SNaPshot assay.
F-18 FDG PET
F-18 FDG PET imaging was performed with a dedicated
PET/CT scanner (Gemini; Philips, Milpitas, CA USA)
that consisted of a dedicated germanium oxyorthosilicate
full-ring PET scanner and a dual-slice helical CT scanner.
The standard patient preparation included at least 8
hours of fasting and patients with a serum glucose level <
120 mg/dL before F-18 FDG administration. PET/CT
imaging was performed 60 minutes after the injection of
F-18 FDG. Sixty minutes after the administration of F-18
FDG, low-dose CT (30 mAs, 120 kV) covering the area
from the base of the skull to the proximal thighs was per-
formed for the purpose of attenuation correction and
precise anatomic localization. Thereafter, an emission
scan was conducted in the three-dimensional mode. The
emission scan time per bed position was 3 minutes and 9
bed positions were acquired. PET data were obtained
using a high-resolution whole body scanner with an axial
field of view of 18 cm. The average total PET/CT exami-
nation time was 30 minutes. After scatter and decay cor-
rection, PET data were reconstructed iteratively with
attenuation correction and were reoriented in axial, sagit-
tal, and coronal slices. A row action maximum-likelihood
algorithm was used for three-dimensional reconstruc-
tion.
Visual assessment and quantitative analysis
Experienced nuclear medicine physicians blinded to the
results of other imaging modalities and the pathologic
findings reviewed the F-18 FDG PET/CT scans. The
medical records, including treatment regimens, other
medical imaging modalities, and fine needle aspiration
biopsies, were reviewed and analyzed. Two experienced
nuclear medicine physicians independently reviewed the
PET/CT images and any disagreement was resolved by
consensus. To calculate the SUVmax, manually-defined
circular regions of interest (ROI) were drawn on the
attenuation-corrected emission images throughout the
axial planes where a suspicious lesion could be delin-
eated.
Statistical analysis
The association between the mean SUVmax and clinico-
pathologic factors was analyzed using a two-tailed Pear-
son's chi-squared or Fisher's exact test as appropriate.
Differences in groups for the mean SUVmax values were
Table 1: Primers for amplification and allele frequencies of hypoxia-related polymorphisms
Gene SNP name
(rs number)
Primer sequence Tm
VEGFA +936C>T
(rs3025039)
Forward CACTTTGGGTCCGGAGGG
Reverse TGATTTAGCAGCAAGAAAAATAAA 55
Genotyping GGCGAATCCAATTCCAAGAGGGACC
HIF1A P582S
(rs11549465)
Forward TATATCCCAATGGATGATGACTT
Reverse TTCTTGTATTTGAGTCTGCTGG 55
Genotyping GTTACGTTCCTTCGATCAGTTGTCA
HIF1A A588T
(rs11549467)
Forward AGATTTAGACTTGGAGATGTTAGCTC
Reverse AATACTGTAACTGTGCTTTGAGGAC 55
Genotyping GTTGTCAYCATTAGAAAGCAGTTCC
SLC2A1 -2841A>T
(rs710218)
Forward CCTTTGCACATGCTCTTC
Reverse GCCACCTTGTCCTTCTCT 60
Genotyping CCTGTGGTACAAGTTCTGC
APEX1 D148E
(rs1130409)
Forward CAGTGCCCACTCAAAGTT
Reverse CTTGCGAAAGGCTTCAT 60
Genotyping GGCCTTCCTGATCATGCTCCTCKim et al. Journal of Experimental & Clinical Cancer Research 2010, 29:69
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tested using one-way ANOVA or the t-test as appropri-
ate. For the t-test, we assessed the equality of variance
with Levene's test. Differences were considered signifi-
cant when the P value was < 0.05. Statistical analysis and
Kaplan-Meier curves were performed with SPSS (version
14.0; SPSS, Inc., Chicago, IL, USA).
Results
1. Patient characteristics
The median patient age was 65 years (range, 28-84 years);
114 (74.0%) of the patients were men. The majority
(83.1%) of patients had stage III or IV disease. Seventy-
five of the patients (48.7%) had adenocarcninomas and 79
(51.3%) had squamous cell carcinomas. The clinicopatho-
logic data are summarized in Table 2.
2. Genotype information
The Hardy-Weinberg equilibrium was observed for all
SNPs. The frequencies of the AA, AT, and TT genotypes
of  SLC2A1  -2841A>T were 51.7%, 37.7%, and 10.6%,
respectively. Other genotype frequencies are listed in
Table 3. Using the Haploview v. 4.0 software package, we
constructed haplotypes of HIF1A  Pro582Ser and
Ala588Thr. HIF1A was nearly monomorphic and CCGG
was most commonly observed with a frequency of 81.6%.
3. Association of SNPs with the mean SUVmax
No statistical differences were observed between the
SNPs and the mean SUVmax when the patients were not
stratified. We classified the patients into two groups
according to the histologic cell type (adenocarcinoma and
squamous cell carcinoma). There were no significant dif-
ferences between the SNPs and the mean SUVmax in
patients with adenocarcinomas. In patients with
squamous cell carcinomas, the mean SUVmax of the
SLC2A1 TT and AA + AT genotypes (recessive model)
were 10.64 ± 2.26 and 9.07 ± 2.79, respectively, with no
statistical significance (P = 0.130, Table 4).
4. Association of SNPs on the mean SUVmax in squamous 
cell carcinomas
We analyzed subgroups according to the combinations of
SLC2A1, VEGFA, APEX1, and HIF1A polymorphisms in
patients with squamous cell carcinomas. The SLC2A1 -
2841A>T polymorphism was significantly associated
with the mean SUVmax in the recessive model of SLC2A1
-2841A>T in combination with the APEX1  polymor-
phism (Table 5). For the TT genotype of APEX1, the
SLC2A1 TT genotype had a higher SUVmax than the AA
+ AT genotype (12.47 ± 1.33 versus 8.46 ± 2.90, respec-
tively;  P  = 0.028, Table 5). The other combinations of
SLC2A1, VEGFA, and HIF1A polymorphisms were not
associated with the mean SUVmax.
Discussion
Although there have been several reports that have
described an association between hypoxia-related genes
and SUVmax in patients with lung cancer [17,18], this is
the first study that has evaluated the impact of SLC2A1
gene polymorphisms on FDG-uptake in conjunction with
the HIF-1a-activated transcription pathway in patients
with NSCLC. With this pathway-based approach, we
have demonstrated that SLC2A1 TT is statistically associ-
ated with a high FDG-uptake in combination with the TT
genotype of APEX1 in patients with the squamous cell
type of NSCLC. Interestingly, the SLC2A1 TT and APEX1
Table 2: Patient characteristics
Adenocarcinoma Squamous cell carcinoma
Age
Male 64.2 ± 8.5 (n = 41) 66.0 ± 8.1 (n = 73)
Female 59.2 ± 10.8 (n = 34) 67.7 ± 10.0 (n = 6)
Smoking habit
Never 35 (46.7%) 7 (8.9%)
Smoker 40 (53.3%) 72 (91.1%)
Stage
Stage I + II 14 (18.7%) 12 (15.2%)
Stage III + IV 61 (81.3%) 67 (84.8%)
T stage
1 12 (16.0%) 4 (5.1%)
2 2 (2.7%) 8 (10.1%)
3 19 (25.3%) 43 (54.4%)
4 42 (56.0%) 24 (30.4%)Kim et al. Journal of Experimental & Clinical Cancer Research 2010, 29:69
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TT genotypes are risk alleles associated with the clinical
outcome of several diseases, including diabetes and other
malignancies [19,20].
F D G - u p t a k e  o f  P E T ,  e x p r e s s e d  a s  t h e  S U V m a x ,  i s
largely dependent on glucose metabolism in lung cancer.
SLC2A1  is the primary glucose transporter of glucose
metabolism and overexpression of SLC2A1 has an impor-
tant role in the survival and rapid growth of cancer cells
in a suboptimal environment [2]. High FDG uptake is
associated with reduced overall survival and disease-free
survival of patients [21].
SLC2A1 protein expression was shown to differ based
o n  t h e  h i s t o l o g i c  t y p e  i n  p a t i e n t s  w i t h  N S C L C .  T h e
expression of SLC2A1 in squamous cell carcinomas was
higher than adenocarcinomas[2]. Growth rate has been
reported to be faster in squamous cell carcinomas, but
slower in adenocarcinomas [22], and lung tumor growth
correlates with glucose metabolism [23]. In our study, the
Table 3: Allele frequencies of SLC2A1, VEGFA, APEX1, and HIF1A polymorphisms
Target gene polymorphism
(rs number)
Genotype No. patients (%) Allele frequencies Hardy-Weinberg 
equilibrium
SLC2A1 -2841A>T AA 78 (51.7%) A:T 0.705:0.295 0.2579
(rs710218) AT 57 (37.7%)
TT 16 (10.6%)
VEGFA +936C>T CC 102 (67.1%) C:T 0.819:0.181 0.2579
(rs3025039) CT 45 (29.6%)
TT 5 (3.3%)
APEX1 Asp148Glu TT 55 (36.4%) T:G 0.589:0.411 0.3929
(rs1130409) TG 68 (45.0%)
GG 28 (18.5%)
HIF1A Pro582Ser CC 139 (90.8%) C:T 0.954:0.046 0.5541
(rs11549465) CT 14 (9.2%)
TT 0 (0.0%)
HIF1A Ala588Thr GG 137 (90.1%) G:A 0.951:0.049 0.5219
(rs11549467) GA 15 (9.9%)
AA 0 (0.0%)
Table 4: Association between gene polymorphisms of hypoxia-related genes and the mean SUVmax in patients with squamous cell 
carcinoma (n = 78)
Genes Genotype SUVmax P* Domonant model SUVmax P† Recessive mode SUVmax P†
SLC2A1 -2841A>T AA (n = 41) 9.40 ± 2.63 0.155 AA 9.40 ± 2.63 0.565 AA + AT 9.07 ± 2.79 0.130
AT (n = 29) 8.60 ± 2.98 AT + TT 9.04 ± 2.94 TT 10.64 ± 2.26
TT (n = 8) 10.64 ± 2.26
VEGFA +936C>T CC (n = 54) 9.29 ± 2.66 0.816 CC 9.29 ± 2.66 0.774 CC + CT 9.20 ± 2.80 0.663
CT (n = 20) 8.95 ± 3.23 CT + TT 9.10 ± 3.06 TT 9.83 ± 2.25
TT (n = 4) 9.83 ± 2.25
APEX1 Asp148Glu TT (n = 28) 8.89 ± 3.04 0.522 TT 8.89 ± 3.04 0.412 TT + TG 9.30 ± 2.90 0.672
TG (n = 34) 9.64 ± 2.79 TG + GG 9.43 ± 2.62 GG 8.97 ± 2.23
GG (n = 16) 8.97 ± 2.23
HIF1A Pro582Ser CC (n = 69) 9.32 ± 2.84 0.671
CT (n = 10) 8.92 ± 2.35
HIF1A Ala588Thr GG (n = 68) 9.18 ± 2.74 0.664
GA (n = 10) 9.59 ± 3.11
*ANOVA † t-testKim et al. Journal of Experimental & Clinical Cancer Research 2010, 29:69
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significance of SLC2A1  gene polymorphisms on FDG-
uptake was consistently observed for squamous cell carci-
nomas, but not for adenocarcinomas.
The functional effect of the SLC2A1 -2841A>T poly-
morphism has not been completely characterized. A
hypoxia response element (HRE) is located 400 bp down-
stream from the A-2841T site. The close proximity of the
polymorphism to the HRE may modify the binding affin-
ity of HIF-1 and may alter the efficiency of the promoter
and expression of SLC2A1 [19]. The effect of the SLC2A1
polymorphism could be due to causative or linkage dis-
equilibrium.
Although the XbaI polymorphism of SLC2A1 is a well-
known polymorphism in diabetes, the association
between diabetic nephropathy and the XbaI polymor-
phism in the SLC2A1 gene has been controversial in sev-
eral case-control studies [24-26]. Furthermore, the
polymorphic XbaI site is located on the second intron of
the  SLC2A1  gene. The allele cannot possibly cause
changes in the protein sequence, and thus no change
would be expected in SLC2A1 expression. Therefore, we
did not evaluate the XbaI polymorphism of SLC2A1.
APEX1  promotes transcriptional activation of HIF-1
and HLF [12]. Reduced APEX1 protein expression dem-
onstrated a reduction in tumor volume and FDG uptake,
indicating that APEX1  affects glucose metabolism and
cellular proliferation [27]. Homozygosity (TT genotype)
for the APEX1 Asp148Glu variant genotype was signifi-
cantly associated with a poorer overall survival [20].
Based on the observation that the statistical signifi-
cance of a SLC2A1 gene polymorphism was clearly iden-
tified in combination with an APEX1  gene
polymorphism, we reasoned that the clinical impact of a
SLC2A1  gene polymorphism on FDG-uptake might be
minimal in late stage NSCLC. The significant effect of the
APEX1  T T  g e n o t y p e  o n  t h e  m e a n  S U V m a x  w i t h  a
SLC2A1 gene polymorphism in this study suggests a role
for the APEX1  Asp148Glu polymorphism in FDG-
uptake. However, an additional functional study for the
effect of APEX1 gene polymorphisms on FDG-uptake at
the cellular level should be performed.
We did not analyze SLC2A1 polymorphisms based on
the genotype of HIF1A due to the nearly monomorphic
status of HIF1A (the frequencies of HIF1A minor alleles
were < 1%). These genotype frequencies were very similar
to frequencies reported in a previous study by Kuwai et
al. [28]. Kuwai and colleagues reported a CT polymor-
phism in 11%, but an absence of TT in the Japanese popu-
lation. Moreover, despite the association of HIF1A
polymorphisms with HIF-1a expression, there was no
association of polymorphisms with the expression of the
down-stream proteins encoded by SLC2A1 and VEGFA
[8].
VEGFA is the major mediator of angiogenesis and vas-
cular permeability. Transcription of VEGFA  under
hypoxic conditions depends on HIF-1a induction.
Although FDG-uptake has been correlated significantly
with VEGFA expression in patients with NSCLC [18], we
did not observe an effect of the VEGFA+936C>T poly-
morphism on FDG-uptake. An association between the
VEGFA+936C>T polymorphism and FDG-uptake has
been rarely reported for patients with NSCLC. Wolf et al.
[11] reported that the VEGFA+936C>T polymorphism is
associated with FDG-uptake in breast cancer patients.
The FDG-uptake data in the study by Wolf et al. [11] was
expressed as categorical data (low, medium, and high
uptake) and not as a SUVmax, as in the present study;
thus, we cannot directly compare the values of SUVmax
obtained in the present study. Another possible explana-
tion was a difference in the study population. The popula-
Table 5: Association between the SLC2A1 -2841A>T gene polymorphism and the mean SUVmax in patients with squamous cell carcinoma 
according to the APEX1 genotype
APEX1 
genotype
Gene genotype SUVmax P*D o m i n a n t  
model
SUVmax P† Recessive 
mode
SUVmax P†
TT SLC2A1 -2841A>T AA (n = 13) 8.68 ± 2.40 0.086 AA 8.68 ± 2.40 0.742 AA + AT 8.46 ± 2.90 0.028
AT (n = 12) 8.22 ± 3.47 AT + TT 9.07 ± 3.58 TT 12.47 ± 1.33
TT (n = 3) 12.47 ± 1.33
TG SLC2A1 -2841A>T AA (n = 20) 9.72 ± 3.00 0.984 AA 9.72 ± 3.00 0.857 AA + AT 9.66 ± 2.93 0.932
AT (n = 9) 9.53 ± 2.94 AT + TT 9.54 ± 2.56 TT 9.54 ± 2.00
TT (n = 5) 9.54 ± 2.01
GG SLC2A1 -2841A>T AA (n = 8) 9.81 ± 1.97 AA 9.81 ± 1.97 0.134 AA + AT 8.97 ± 2.23
AT (n = 8) 8.13 ± 2.26 AT + TT 8.13 ± 2.26 TT
TT (n = 0)
*ANOVA
† t-testKim et al. Journal of Experimental & Clinical Cancer Research 2010, 29:69
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tion in the study by W olf et al. [11] was breast cancer
patients, while the study population in the present study
was lung cancer patients. Recently, several functional
SNPs of VEFGA have been identified that are associated
with survival in patients with early stage NSCLC [29,30].
Well-documented functional SNPs, such as VEGFA
+405G>C and -460T>C, should be evaluated to identify
the association between VEGFA  gene polymorphisms
and FDG-uptake.
There were several limitations to this study. We did not
evaluate the association between hypoxia-related gene
polymorphisms and FDG-uptake in patients with early
stage NSCLC. Although the SLC2A1 -2841A>T polymor-
phism in combination with the APEX1 Asp148Glu poly-
morphism was associated with FDG uptake in this study,
this result was based on a statistical comparison rather
than a functional study. Another limitation was the
potential effect of unknown SNPs of hypoxia-related
genes on FDG-uptake, as we only analyzed documented-
functional SNPs. Thus, additional investigations of poly-
morphisms in entire hypoxia-induced pathway on FDG-
uptake are needed.
In summary, the SLC2A1 -2841A>T polymorphism was
associated with FDG-uptake in combination with the
APEX1 TT genotype in patients with squamous cell car-
cinoma. Our findings suggest that a newly developed
tracer for PET could be affected by genetic polymor-
phisms. However, further studies are required to validate
these results.
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